Introduction to common adverse reactions of Odevixibat and how to deal with them

Odevixibat (Odevixibat) is an oral bile salt transporter (IBAT) inhibitor, mainly used to treat rare cholestatic diseases such as progressive familial intrahepatic cholestasis (PFIC). Although the drug has shown good efficacy in improving itching and reducing serum bile acid levels, certain adverse reactions may still occur during clinical use, especially in pediatric patients, which requires more attention. Common adverse reactions mainly involve the gastrointestinal system, and symptoms related to changes in bile metabolism may also occur.

The most common adverse reaction is diarrhea. This is because the drug inhibits the reabsorption of bile salts in the intestine, resulting in an increase in the concentration of bile salts in the intestine, causing osmotic diarrhea. Diarrhea symptoms in most patients are mild, often occur in the early stages of treatment, and usually resolve as the body gradually adapts. It is recommended that patients appropriately reduce fat intake in the early stages of treatment and use antidiarrheal drugs under the guidance of a doctor if necessary. If diarrhea is severe or continues to affect your life, seek medical attention immediately and evaluate whether the dose needs to be adjusted or the medication needs to be temporarily discontinued.

In addition, some patients may experience gastrointestinal discomfort such as abdominal pain, nausea, vomiting, and bloating. These symptoms are mostly mild to moderate and usually do not require discontinuation of treatment. It is recommended to take the medication after meals and monitor changes in symptoms. If symptoms worsen or persist, you should promptly report to your doctor to evaluate whether it is related to the drug. Some children may experience weight loss, loss of appetite and other problems after long-term medication. Parents should pay attention to daily dietary nutritional support and conduct regular weight and growth monitoring.

Some clinical studies have also observed fluctuations in liver function indicators such as elevated transaminases. Therefore, liver function and bile acid levels need to be monitored regularly during medication so that treatment strategies can be adjusted in a timely manner. In general, the adverse reactions of orvixibat are mostly controllable and reversible. The key lies in early identification, reasonable response and individualized management. Patients should strictly follow the doctor's instructions when taking medication, maintain good communication with the doctor, and report abnormal symptoms in a timely manner, so as to improve medication safety and obtain better treatment effects.

Reference materials:https://www.drugs.com/